Source: International Congress 2018 – The airway microbiome across the spectrum of airway disease
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. Duarte Ferreira Dantas (Lisbon, Portugal), D. Silva (Lisbon, Portugal), I. Duarte (Lisbon, Portugal), R. Bernardes (Lisbon, Portugal), T. Sá (Lisbon, Portugal), J. Cardoso (Lisbon, Portugal). Bronchiectasis exacerbations by Pseudomonas aeruginosa: differences and similarities. 5316

Member's Comments

No comment yet.

Related content which might interest you: Pseudomonas aeruginosa isolates in bronchiectasis: Wath particulaties and risk factors? Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis Source: Eur Respir J 2006; 28: 974-979 Year: 2006 Pseudomonas aeruginosa infection and exacerbations in bronchiectasis: more questions than answers Source: Eur Respir J, 51 (2) 1702497; 10.1183/13993003.02497-2017 Year: 2018 Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD. Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020 Variability of ß-lactamase resistance Pseudomonas aeruginosa genes infecting patients with cystic fibrosis Source: Virtual Congress 2021 – Back to infection basics Year: 2021 Pseudomonas aeruginosa and antibiotic resistance in acute exacerbations of COPD (AECOPD) Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa Year: 2009 Does a single Pseudomonas aeruginosa isolation predict COPD mortality? Source: Eur Respir J 2014; 44: 794-797 Year: 2014 Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis Source: Eur Respir J 2005; 26: 651-656 Year: 2005 Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients Source: International Congress 2015 – Advances from translational research in respiratory infections Year: 2015 Pseudomonas aeruginosa drug susceptibility in patients hospitalized with COPD exacerbation and bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 541s Year: 2001 Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors Source: Eur Respir J 2010; 35: 598-615 Year: 2010 Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003 Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung Source: Eur Respir J , 49 (4)  1602108; DOI: 10.1183/13993003.02108-2016 Year: 2017 Pseudomonas aeruginosa colonisation in patients without bronchiectasis Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014 Inhaled corticosteroid use and its association with Pseudomonas aeruginosa infection in COPD Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 COPD and pseudomonas aeruginosa, an association Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014 Enterobacteriaceae and Pseudomonas aeruginosa in community-acquired pneumonia: the reality after a decade of uncertainty? Source: Eur Respir J 2010; 35: 473-474 Year: 2010 Clinical and microbiological characteristics of Pseudomonas aeruginosa isolates from patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 58s Year: 2005 Pseudomonas aeruginosa infections Source: Respipedia Article Year: 2018